# Metronomic Versus Conventional Chemotherapy in as Maintenance Treatment in mCRC

> **NCT02893540** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 250 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT02893540
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-09
- **Primary completion:** 2018-12
- **Final completion:** 2019-08
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2016-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02893540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02893540, "Metronomic Versus Conventional Chemotherapy in as Maintenance Treatment in mCRC". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT02893540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*